Skip to main content

Table 7 Effect of treatment exposure for combined sulforaphane (SF) and placebo (PL) groups at 15 weeks and for SF-only group at 30 weeks

From: Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder

Biomarker

Intervention (exposure)

Change

N

F-statistic

p value

Free reduced GSHa

 15 weeks

40

1.95

0.170

–

 30 weeks

22

0.75

0.485

 

Total GSHa

 15 weeks

40

0.11

0.746

–

 30 weeks

22

0.06

0.946

 

GSSGa

 15 weeks

40

0.15

0.701

↑

 30 weeks

22

2.32

0.124

 

Free GSH:GSSG

 15 weeks

40

3.90

0.055

↓

 30 weeks

22

8.12

0.003

 

Total GSH:GSSG

 15 weeks

40

1.32

0.258

↓

 30 weeks

22

3.60

0.046

 
  1. Bold signifies p < 0.05
  2. MANOVA test for repeated measures (compared to baseline at 0 weeks); analysis includes participants from the initial PL group while they were on SF at 22 and 30 weeks (their first 7 and 15 weeks of exposure)
  3. aNatural log transformed
Back to article page

Molecular Autism

ISSN: 2040-2392